Chemical formula: C₂₂H₂₂N₆O₇S₂ Molecular mass: 546.576 g/mol PubChem compound: 5481173
Ceftazidime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J01DD02 | Ceftazidime | J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DD Third-generation cephalosporins |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| CEFTAZIDIME Powder for solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Ceftazidime is an active ingredient of these brands:
Brazil (BR)Cyprus (CY)Ecuador (EC)
Estonia (EE)Hong Kong (HK)Israel (IL)Italy (IT)Mexico (MX)Netherlands (NL)
New Zealand (NZ)South Africa (ZA)Spain (ES)
Tunisia (TN)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
